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SCIENTIFIC ARTICLE
Dupuytren Diathesis and Genetic Risk
Guido H. Dolmans, MD, Geertruida H. de Bock, PhD, Paul M.Werker, MD, PhD
Purpose Dupuytren disease (DD) is a benign fibrosing disorder of the hand and fingers.
Recently, we identified 9 single nucleotide polymorphisms (SNPs) associated with DD in a
genome-wide association study. These SNPs can be used to calculate a genetic risk score for
DD. The aim of this study was to test whether certain clinical characteristics (including the
DD diathesis features) of patients with DD are associated with a high genetic risk score.
Methods Between 2007 and 2010, we prospectively invited all DD patients (1,120 in total) to
participate. Clinical characteristics were noted using patient- and doctor-completed ques-
tionnaires, and blood was obtained for DNA analysis. We analyzed a total of 933 subjects
with genetic and clinical data. The 9 previously identified DD SNPs were used to calculate
a weighted genetic risk score. Patients were categorized into high and low genetic risk score
groups, according to their weighted genetic risk score. Logistic regression was performed to
study the association of clinical characteristics with a high genetic risk score.
Results In a univariate regression model, patients with an age of onset of DD younger than
50 years, a family history positive for DD, knuckle pads, and Ledderhose disease were
statistically significantly associated with a high genetic risk score. In an additional analysis
using high and low genetic risk groups that deviate further from the median, Ledderhose
disease was no longer significantly associated with DD.
Conclusions Patients with DD who present with these diathesis features, and predominantly
patients with knuckle pads, are more likely to carry more risk alleles for the discovered DD
SNPs than patients without these diathesis features.
Clinical relevance These markers may prove useful in predicting disease progression or
recurrence. (J Hand Surg 2012;37A:2106–2111. Copyright © 2012 by the American Society
for Surgery of the Hand. All rights reserved.)
Key words Dupuytren diathesis, Dupuytren disease, Dupuytren contracture, genetics,
genetic risk score.o
sDUPUYTREN DISEASE (DD) is a benign fibrosingdisorder of the palmar fascias of the hand andfingers leading to the formation of nodules and
cords. Often these cords contract, causing flexion con-
tractures of the fingers. The prevalence of DD has been
reported to vary between 0.2 and 56%.1 The prevalence
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frequently in white males.3 Standard treatment consists
f collagenase injection and percutaneous division or
urgical excision of the nodules and cords.4,5 At pres-
ent, the disease is incurable and recurrence rates fol-
lowing treatment vary from 8% to 66%, depending on
Freek Corsten, Nirvana Kornmann, and Sterre Payens for their administrative work; and all the indi-
vidualswithDupuytren disease for participating in this study.
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DUPUYTREN DIATHESIS AND GENETIC RISK 2107the treatment modality and definition of recurrence.5–7
DD is associated with several environmental factors,
such as alcohol consumption, smoking, and antiepilep-
tic drug use, as well as with diseases such as diabetes
mellitus and liver disease.8
The way DD develops varies over time. Some clin-
ical characteristics of patients with DD are related to a
more aggressive course of the disease or diathesis. In
1963, Hueston9 postulated the idea of a DD diathesis
and described 4 factors defining this subset of disease:
early onset of disease, bilateral involvement, positive
family history, and the presence of ectopic lesions
(knuckle pads, Ledderhose disease, and Peyronie dis-
ease). In 2006, male sex as a diathesis factor was added,
“early onset of disease” was refined to age of onset
younger than 50 years, and the ectopic lesions were
restricted to the presence of knuckle pads only.2 Fea-
tures of the DD diathesis were used also in a scoring
system by Abe et al.10 in 2004 to evaluate the risk of
recurrence and extension of DD for a Japanese popu-
lation, implicating a more aggressive course of the
disease. These authors suggested the addition of radial
side involvement and little finger involvement to the
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FIGURE 1: Indiathesis scoring list.
JHS Vol A, OThe clustering of DD in families has long been
recognized and most genetic studies have reported an
autosomal dominant inheritance pattern.11,12 Recently,
we suggested that DD is a complex genetic disorder, in
which several genetic and environmental risk factors
are involved, each contributing to disease susceptibil-
ity.13 Nine SNPs associated with DD were identified in
a 2-stage genome-wide association study in 2,325 DD
patients and 11,562 population controls. These SNPs
represent the presently known genetic DD profile and
can be used to calculate a genetic risk score for DD in
each patient; the more risk alleles a patient carries, the
higher the genetic risk score will be for that patient.14
We hypothesized that there is an association between
certain clinical characteristics and the genetic risk score
of patients with DD. Therefore, the aim of this study
was to test whether clinical characteristics (including
the diathesis features) of DD patients are associated
with a high genetic risk score.
MATERIALS AND METHODS
Between 2007 and 2010, we prospectively invited all
patients evaluated for a diagnosis of DD at the outpa-
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uptient clinics of the plastic surgery departments of 6
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2108 DUPUYTREN DIATHESIS AND GENETIC RISKhospitals in the Netherlands to participate. In this pe-
riod, a total of 1,120 patients gave their consent (see
flow chart, Figure 1). Patients were diagnosed by plastic
surgeons with substantial clinical experience in treating
DD. The diagnosis was based on the presence of char-
acteristic nodules and/or cords in the palm of the hand
and/or digits, with or without contracture of the digits.
Written informed consent was acquired from all pa-
tients, with institutional review board approval. Patients
were asked to complete a questionnaire inquiring about
details concerning their clinical characteristics includ-
ing age of onset, familial involvement, level of educa-
tion, hand labor, medical history, and medications. A
positive family history was defined as the presence of at
least 1 other affected family member as noted by the
patient. For 58 patients, the patient’s questionnaire was
not available (Figure 1). The plastic surgeons com-
pleted a separate questionnaire on the clinical charac-
teristics of these patients, including passive extension
deficits in metacarpophalangeal (MCP), proximal inter-
phalangeal (PIP), and distal interphalangeal (DIP)
joints, unilateral or bilateral disease, the number of
rays involved, and the presence of ectopic deposits
(knuckle pads, Ledderhose disease, and Peyronie
disease). For 367 patients, the doctor’s question-
naire was not available (Figure 1). We did not
collect clinical data concerning radial side involve-
ment and little finger involvement as used in the
scoring system by Abe et al.10 Blood was obtained
from all patients for DNA analysis.
Genetic and statistical analysis
Details about genotyping and quality control steps have
been described previously.13 One hundred twenty-nine
TABLE 1. Relevant Clinical Characteristics, Patient




Male 711 (76) 42
Female 222 (24) 14
Age of onset (y)
 50 355 (39) 20
 50 561 (61) 35
Family history for DD
Positive 461 (50) 27
Negative 468 (50) 29
DD, Dupuytren disease.DNA-samples did not pass standard quality control and
JHS Vol A, Owere excluded from further analysis (Figure 1). The 9
SNPs that were found to be associated with DD were at
an individual basis used to calculate a weighted genetic
risk score (wGRS).
The wGRS of each patient was calculated by multi-
plying the number of risk alleles per SNP by the weight




n 367 (%) Chi-square
) 290 (79) P  .104
) 77 (21)
) 147 (41) P  .251
) 211 (59)
) 191 (52) P  .208
) 175 (48)
TABLE 2. Relevant Clinical Characteristics,
Doctor’s Questionnaire (N  566)
Clinical Characteristics N (%)
Number of affected rays
 3 390 (74)
 3 139 (26)
Total passive extension
deficit
 45o 298 (54)




















3 (52for that SNP, taking the sum across the SNPs, and
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where i is the SNP, n is the number of SNPs, wi is the
weight for SNP i, and Xi is the number of risk alleles.
The natural log of the odds ratio (OR) for each allele
was used for the weight. For this wGRS calculation,
PLINK software (version 1.07),15 a tool set for genetic
analysis, was used.
The more risk alleles that are carried by a patient, the
higher the wGRS. The wGRS scores were primarily
divided in 2 categories (low and high score), where all
scores below the median were considered as low score
and all the scores equal to or higher than the median
were considered as high score. An additional analysis
was performed in which the groups were subdivided
into categories that deviated further from the median.
The low genetic risk score group was defined as a
wGRS lower than 1 standard deviation (SD) from the
median and the high genetic risk score group as a
wGRS higher than 1 SD from the median. These cate-
gories were designed arbitrarily.
All data were transcribed categorically by using
FIGURE 2: Histograbinary variables. Because the doctor’s question-
JHS Vol A, Onaire was not available for all patients, a chi-
square test was used to compare the patient groups
with and without a doctor’s questionnaire. We
thereafter performed univariate logistic regression
to study the association of clinical characteristics
with the presence of a high genetic score and
calculated ORs and 95% confidence intervals. P 
genetic risk scores.
TABLE 3. Prediction of Characteristics, Patient’s
Questionnaire, on High Genetic Risk Score Using
a Univariate Logistic Regression Analysis
Variable OR 95% CI P
Sex
Male 1.28 0.94–1.73 .11
Female 1
Age of onset
 50 1.35 1.04–1.77 .03
 50 1
Family history for DD
Positive 1.58 1.22–2.04 .001
Negative 1
CI, confidence interval; DD, Dupuytren disease; OR, odds ratio..05 was considered as statistically significant.
ctober 
2110 DUPUYTREN DIATHESIS AND GENETIC RISKRESULTS
An overview of the clinical characteristics noted in the
patient’s and doctor’s questionnaires is shown in Table
1 and Table 2, respectively. Of the 933 patients who
completed the patient’s questionnaire, 711 (76%) were
male and 222 (24%) were female. There were no dif-
ferences in the frequencies of clinical characteristics
between the patients with or without a completed doc-
tor’s questionnaire (Table 1).
The median wGRS of the 933 patients was 0.009
(ranging from0.044 to 0.064; see also Fig. 2). Based
on the wGRS, 461 patients were below the median and
classified as the low genetic risk score group (including
282 patients with a completed doctor’s questionnaire),
and 472 patients were above the median and classified
as the high genetic risk score group (including 284
patients with a completed doctor’s questionnaire).
The OR of having a high genetic risk score were
significantly greater in patients with an age of onset of
DD Younger than 50 years of age, a family history
positive for DD, knuckle pads, and Ledderhose disease
(Tables 3 and 4). An additional analysis was performed,
in which the low genetic risk score group was defined
TABLE 4. Prediction of Characteristics, Doctor’s
Questionnaire, on High Genetic Risk Score Using
a Univariate Logistic Regression Analysis
Variable OR 95% CI P
Number of affected rays
 3 0.87 0.59–1.28 .47
 3 1
Total passive extension deficit
 45 ° 1.22 0.87–1.71 .24
 45 ° 1
Knuckle pads present
Yes 1.95 1.20–3.18 .01
No 1
Ledderhose disease present
Yes 1.66 1.00–2.76 .05
No 1
Peyronie disease present
Yes 1.26 0.53–3.03 .60
No 1
Bilateral involvement
Yes 1.29 0.92–1.80 .15
No 1
CI, confidence interval; OR, odds ratio.as a wGRS lower than 1 SD from the median and the
JHS Vol A, Ohigh genetic risk score group as a wGRS higher than 1
SD from the median. Age of onset of DD younger than
50 years of age, a family history positive for DD, and
knuckle pads significantly predicted a high genetic
score in this additional analysis (Table 5).
DISCUSSION
The goal of this study was to test whether selected
clinical characteristics of patients with DD were asso-
ciated with a high genetic risk score. Patients were
categorized into high and low genetic score groups
according to their wGRS. In a univariate regression
model, age of onset of DD younger than 50 years of
age, a family history positive for DD, knuckle pads, and
Ledderhose disease were significantly associated with a
high genetic risk score.
The ORs of the significant diathesis features varied
from 1.35 to 1.95, each having only a moderate effect
on predicting a high genetic risk score. This is related to
the fact that the study population was primarily divided
into 2 large subgroups (genetic risk scores higher or
lower than the median), in which most patients had a
genetic score with a value almost equal to the median.
When the groups were further subdivided into catego-
ries that deviated 1 SD from the median, age of onset of
TABLE 5. Prediction of the Significant Diathesis
Features on High Genetic Risk Score in an
Additional Analysis Using Univariate Logistic
Regression*
Variable OR 95% CI P
Age of onset
 50 1.92 1.18–3.12 .009
 50 1
Family history for DD
Positive 1.92 1.20–3.10 .007
Negative 1
Knuckle pads present
Yes 4.40 1.76–10.98 .001
No 1
Ledderhose disease present
Yes 1.44 0.59–3.51 .42
No 1
CI, confidence interval; OR, odds ratio.
*For this additional analysis, the low genetic risk score group was
defined as a wGRS lower than 1 SD from the median and the high
genetic risk score group as a wGRS higher than 1 SD from the
median.DD younger than 50 years of age, a family history
ctober 
DUPUYTREN DIATHESIS AND GENETIC RISK 2111positive for DD, and knuckle pads remained significant
with, as expected, larger effect sizes (Table 5). The
presence of Ledderhose disease ceased to be significant
in the additional analysis and was only just significant
in the primary analysis. Further research has to demon-
strate whether Ledderhose disease is really associated
with a high genetic risk score.
The clinical characteristics that were statistically sig-
nificant in this study are all features of the DD diathesis
defined by Hueston9 and later revisited by Hindocha et
al.9 In the revisited DD diathesis, the definition of
ectopic lesions was restricted to the presence of knuckle
pads.2 In our study, the presence of knuckle pads re-
vealed the highest OR of all the significant clinical
characteristics. Therefore, the presence of knuckle pads
can be seen as the diathesis feature predominantly as-
sociated with a high genetic risk score.
Male sex and bilateral disease, 2 other DD diathesis
features, were not associated with a high genetic score.
The former can be easily explained, because the 9 DD
susceptibility SNPs are not located on the sex chromo-
somes. Therefore, an analysis using these SNPs will not
show differences related to sex. The latter we consider
as a less specific characteristic, because bilateral disease
occurs in many patients over time and the survey time
point influenced this factor. Peyronie disease was also
not associated with a high genetic score. In 36% of
doctor’s questionnaires, Peyronie disease was not
scored (Table 2), perhaps because of hesitance of the
doctor to ask about this issue. This might have had an
effect on the results.
The strengths of this study were the prospective
design and the large cohort of patients who have been
characterized. Limitations of this study were the lack of
follow-up, the use of nonvalidated questionnaires, and
the fact that, in only 566 patients, the doctor’s question-
naire was completed. Because patients presented to the
outpatient clinics for evaluation of their disease, pre-
sumably because of concern about their condition, there
might have been a selection bias.
DD patients who present with an age of onset
younger than 50 years, a positive family history, or
ectopic disease (particularly with knuckle pads) are
more likely to carry more risk alleles for the discovered
DD SNPs than patients without these diathesis features.
It is reassuring to find that there was a relation between
certain diathesis features and the recently identified DD
risk genotypes.
JHS Vol A, OWe know that the diathesis features of DD can lead
to a more aggressive disease. It is to be expected that the
more risk alleles a patient carries (the higher the genetic
risk score), the more aggressive the disease will be. We
are currently planning the follow-up for patients in this
study to answer this question. It would be interesting to
investigate the relationship between genetics and the
course of the disease and especially the occurrence of
recurrent disease.
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